IPHA (Innate Pharma, S.A.) Likuiditas cepet

Innate Pharma S.A. (IPHA) operates independently of economic cycles, as demand for oncological innovations remains stable. The company generates revenue by licensing its NK-cell activation system, receiving milestone payments and royalties from major pharmaceutical behemoths. The market price confirmed by this chart, where the indicator stands at 0.61, underscores the high value of unique developments that grant the business the pricing power to independently determine the terms of antibody deals.

This ratio serves as a critical solvency filter, determining the issuer's ability to instantaneously settle its obligations. The metric aggregates cash and accounts receivable, completely excluding low-liquidity inventories from the calculation. The trend of the quick ratio signals the presence of a real financial reserve. For Innate Pharma S.A. (IPHA), such liquidity is bolstered by patent ownership while delegating testing, which minimizes capital expenditures and dependence on contractors.